BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20178453)

  • 1. Utility of multivariate analysis in support of in vitro metabolite identification studies: retrospective analysis using the antidepressant drug nefazodone.
    Schneider RP; Zhang H; Mu L; Kalgutkar AS; Bonner R
    Xenobiotica; 2010 Apr; 40(4):262-74. PubMed ID: 20178453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.
    Kalgutkar AS; Vaz AD; Lame ME; Henne KR; Soglia J; Zhao SX; Abramov YA; Lombardo F; Collin C; Hendsch ZS; Hop CE
    Drug Metab Dispos; 2005 Feb; 33(2):243-53. PubMed ID: 15523046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
    Bauman JN; Frederick KS; Sawant A; Walsky RL; Cox LM; Obach RS; Kalgutkar AS
    Drug Metab Dispos; 2008 Jun; 36(6):1016-29. PubMed ID: 18332080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes.
    Rotzinger S; Baker GB
    Eur Neuropsychopharmacol; 2002 Apr; 12(2):91-100. PubMed ID: 11872324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms.
    Li AC; Shou WZ; Mai TT; Jiang XY
    Rapid Commun Mass Spectrom; 2007; 21(24):4001-8. PubMed ID: 18000840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.
    Jurima-Romet M; Wright M; Neigh S
    Br J Clin Pharmacol; 1998 Mar; 45(3):318-21. PubMed ID: 10896409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.
    Kalgutkar AS; Henne KR; Lame ME; Vaz AD; Collin C; Soglia JR; Zhao SX; Hop CE
    Chem Biol Interact; 2005 Jun; 155(1-2):10-20. PubMed ID: 15978881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS.
    Mao Y; Huang MQ; Xia YQ; Jemal M
    J Pharm Biomed Anal; 2007 Apr; 43(5):1808-19. PubMed ID: 17236738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements.
    Peterman SM; Duczak N; Kalgutkar AS; Lame ME; Soglia JR
    J Am Soc Mass Spectrom; 2006 Mar; 17(3):363-75. PubMed ID: 16442304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
    Mayol RF; Cole CA; Luke GM; Colson KL; Kerns EH
    Drug Metab Dispos; 1994; 22(2):304-11. PubMed ID: 8013286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
    Nakada N; Kawamura A; Kamimura H; Sato K; Kazuki Y; Kakuni M; Ohbuchi M; Kato K; Tateno C; Oshimura M; Usui T
    Biopharm Drug Dispos; 2016 Jan; 37(1):3-14. PubMed ID: 26352195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
    Wen B; Ma L; Rodrigues AD; Zhu M
    Drug Metab Dispos; 2008 May; 36(5):841-50. PubMed ID: 18238857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolites and metabolic pathways of mesaconitine in rat liver microsomal investigated by using UPLC-MS/MS method in vitro].
    Bi YF; Liu S; Zhang RX; Song FR; Liu ZQ
    Yao Xue Xue Bao; 2013 Dec; 48(12):1823-8. PubMed ID: 24689241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation.
    Barbhaiya RH; Shukla UA; Chaikin P; Greene DS; Marathe PH
    Eur J Clin Pharmacol; 1996; 50(1-2):101-7. PubMed ID: 8739819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'N-in-one' strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan.
    Li AC; Gohdes MA; Shou WZ
    Rapid Commun Mass Spectrom; 2007; 21(8):1421-30. PubMed ID: 17377936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
    Laroudie C; Salazar DE; Cosson JP; Cheuvart B; Istin B; Girault J; Ingrand I; Decourt JP
    Eur J Clin Pharmacol; 1999 Feb; 54(12):923-8. PubMed ID: 10192752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability.
    Jemal M; Ouyang Z; Zhao W; Zhu M; Wu WW
    Rapid Commun Mass Spectrom; 2003; 17(24):2732-40. PubMed ID: 14673820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.